Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDX21459 in Healthy and HCV-Infected Subjects
NCT02112942Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Mar 2014
- Primary completion
- Jun 2014
- Modality
- Metabolically Activated Prodrugs
01
Overview
Phase 1, randomised, double-blind trial of IDX21459 in chronic hepatitis C (CHC) (3 arms), sponsored by Merck & Co. Primary endpoint: Safety and tolerability assessment up to 35 days. Started Mar 2014; status: terminated.
02
Drugs
IDX21459
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on NCT02112942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02112942.